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INTRODUCTION
The average life expectancy for people 
with severe mental illnesses (SMIs), such 
as schizophrenia or bipolar disorder, is 
7–24 years lower than that for the general 
population.1 Higher prevalence of non-
communicable diseases in people with SMI 
is a key contributor to this disparity,2–5 partly 
driven by socioeconomic disadvantage, 
health-risk behaviours,6,7 and side-effects 
of medications.8–10 Co-existing SMI and 
comorbid conditions may interact, resulting 
in poorer outcomes for both, and access to 
health care for physical problems may also 
be more problematic for people with SMI 
compared to people without SMI.11
In the UK, the prevalence of type 2 diabetes 
(T2DM) is twice as high in people with SMI 
compared with the general population;12 these 
individuals also have an increased incidence 
of acute metabolic emergencies and diabetes 
complications.13-14 National guidelines, 
therefore, recommend regular screening for 
diabetes in people with SMI, with the aim of 
achieving the same standards of care as for 
the general population.15–19 The UK’s primary 
care pay-for-performance programme, the 
Quality and Outcomes Framework (QOF), has 
included quality targets for both diabetes and 
SMI since 2004.20 
Overall, recorded quality of care for 
diabetes has improved substantially 
following the introduction of national quality-
improvement initiatives.21 However, evidence 
is lacking on the appropriateness and 
effectiveness of universal quality targets in 
subgroups of people with diabetes, including 
those with SMI, and little is known about 
how SMI and other risk factors combine 
to affect diabetes outcomes. A linked 
healthcare dataset was used, therefore, 
to investigate, in people with diabetes, the 
impact of SMI on healthcare processes and 
diabetes outcomes, including the use of 
routine primary care services, metabolic 
monitoring, diagnosis and hospitalisation 
rates for cardiovascular disease (CVD), and 
the risk of mortality. The aim of this study 
was to identify potential elements in the 
care pathway that might be associated with 




People with severe mental illnesses (SMIs) have 
reduced life expectancy compared with the 
general population. Diabetes is a contributor to 
this disparity, with higher prevalence and poorer 
outcomes in people with SMI.
Aim
To determine the impact of SMI on healthcare 
processes and outcomes for people with type 2 
diabetes (T2DM).
Design and setting
Retrospective, observational, matched, nested, 
case–control study conducted in England 
using patient records from the Clinical Practice 
Research Datalink, linked to Hospital Episode 
Statistics.
Method
A range of healthcare processes (primary 
care consultations, physical health checks, 
and metabolic measurements) and outcomes 
(prevalence and hospitalisation for cardiovascular 
disease [CVD], and mortality risk) were compared 
for 2192 people with SMI and T2DM (cases) with 
7773 people who had diabetes alone (controls). 
Sociodemographics, comorbidity, and medication 
prescription were covariates in regression models.
Results
When compared with results for participants with 
T2DM only, SMI was associated with increased 
risk of all-cause mortality (hazard ratio [HR] 
1.919, 95% confidence interval [CI] = 1.602 to 
2.300) and CVD-specific mortality (HR 2.242, 95% 
CI = 1.547 to 3.250), higher primary care physician 
consultation rates (incidence rate ratio [IRR] 1.149, 
95% CI = 1.111 to 1.188), more-frequent checks 
of blood pressure (IRR 1.024, 95% CI = 1.003 to 
1.046) and cholesterol (IRR 1.038, 95% CI = 1.019 
to 1.058), lower prevalence of angina (odds ratio 
0.671, 95% CI = 0.450 to 1.001), more emergency 
admissions for angina (IRR 1.532, 95% CI = 1.069 
to 2.195), and fewer elective admissions for 
ischaemic heart disease (IRR 0.682, 95% 
CI = 0.508 to 0.915). 
Conclusion
Monitoring of metabolic measurements was 
comparable for people with T2DM who did, and 
did not, have SMI. Increased mortality rates 
observed in people with SMI may be attributable 
to underdiagnosis of CVD and delays in treatment.
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METHOD
Data sources and participants
The dataset was extracted from Clinical 
Practice Research Datalink (CPRD) GOLD, 
which includes patient information on 
symptoms and diagnoses, referrals to 
specialists and secondary care settings, 
prescriptions issued in primary care, 
diagnostic testing, biometric data, and other 
types of care as routinely provided in primary 
care. Patient characteristics are broadly 
representative of the general UK population 
in terms of age, sex, and ethnicity.22 
Individual patient data were electronically 
linked to external data sources, including 
Hospital Episode Statistics for hospital 
admissions, Office for National Statistics 
for death records, and the Index of Multiple 
Deprivation (IMD) for area deprivation.23–25
A matched, nested, case–control design 
was used. Cases comprised people with 
comorbid SMI and T2DM; people with T2DM 
but no SMI were identified as matched 
controls based on age, sex, and primary care 
practice, with a maximum ratio of 4:1. SMI 
was defined as the presence of at least one 
diagnostic record entry for schizophrenia, 
schizoaffective disorder, bipolar disorder, 
depression, or other affective disorder with 
psychosis in either primary care or hospital-
admission data. Diabetes was classified as 
the presence of diagnostic codes for T2DM 
in primary care or hospital-admission data. 
Cases and controls were included if the 
patient:
• had health records that were up to 
research standard and eligible for 
relevant linkages; 
• was registered with a participating 
primary care practice in England in the 
study period (1 April 2000–31 March 2016); 
• was aged ≥18 years when diagnosed with 
either T2DM or SMI; 
• had a continuous medical record; and 
• could be nested within a matched case–
control cluster. 
Individual follow-up periods started 
on the latter date of either the T2DM 
diagnosis or the beginning of data that 
were up to research standards plus 
15 months, to ensure there was a large 
window for observing baseline participant 
characteristics. Follow-up ended on the 
earlier date of 31 March 2016 or the end 
of data that were up to research standards 
(see Supplementary Figure S1). 
Variables 
The exposure variable was SMI diagnosis. 
Outcome variables were primary care 
consultations, completion of physical 
health checks, metabolic measurements, 
diagnosis and hospitalisation for CVD, and 
risk of all-cause and CVD-specific mortality. 
Primary care consultation rates were 
expressed as the average number of 
face-to-face consultations per year with 
practice-based health professionals in the 
follow-up period. The average number of 
health checks per year was calculated as 
recorded checks on blood pressure (BP), 
serum cholesterol, glycated haemoglobin 
(HbA1c), and body mass index (BMI) as 
incentivised under the QOF for people with 
T2DM. Metabolic measurements were 
expressed by the average levels of BP, 
serum cholesterol, and HbA1c in the study 
period. 
CVD was identified as the presence of 
diagnostic codes recorded in primary care 
data during the follow-up period, with: 
• separate indicators for: 
 − angina; 
 −  myocardial infarction (MI), including 
acute coronary syndrome; 
 − stroke; 
 −  chronic ischaemic heart disease (IHD); 
and 
• a combined indicator for macrovascular 
complications (MI, stroke, and peripheral 
vascular disease [PVD]). 
Hospital admissions for CVD were 
measured as the average number of 
How this fits in 
People with severe mental illnesses 
(SMIs) have poorer physical health and 
a life expectancy that is lower than the 
general population. Diabetes contributes 
significantly to this health inequality. 
National UK guidelines have recommended 
regular screening for diabetes in people 
with SMI and monitoring of metabolic 
risk factors in people with diabetes. This 
study, conducted in England, provides new 
evidence that the monitoring of diabetes 
and metabolic control is no worse for 
people with SMI and diabetes, compared 
with that for people with diabetes 
alone. However, people with SMI are 
underdiagnosed for cardiovascular disease 
(CVD) in primary care and, consequently, 
have poorer access to specialist and 
elective hospital care; this may explain the 
elevated risk of mortality due to CVD in this 
population.
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admissions per year in the follow-up period, 
separated by emergency and elective 
admissions, as well as by diagnosis groups, 
including angina, MI, chronic IHD, and 
stroke. 
Adjustments were made for age, 
ethnicity, and area deprivation — the 
latter was obtained by linking participants’ 
residential postcodes to the 2010 English 
IMD at the Lower Layer Super Output 
Area level, and dividing into quintiles. 
Baseline comorbidities were measured 
by the diagnosis of CVD, hypertension, 
dementia, learning disability, and the 
number of Charlson Comorbidity Index 
(CCI) comorbidities (excluding diabetes 
and diabetes complications) prior to 
follow-up. Baseline medication use was 
determined through documentation of at 
least one prescription for antidepressants 
and antipsychotics (first and second 
generations), or antihypertensive, 
antidiabetes, or lipid-lowering medications 
issued in the 15-month window prior to 
follow-up. Baseline smoking status (as 
a health-risk behaviour) and biometric 
measures (BMI, BP, serum cholesterol, 
and HbA1c) were constructed using the 
most-recent records extracted from the 
15-month window. 
Statistical methods 
A case–control cluster entered the analysis 
only after the patient constituting the ‘case’ 
was diagnosed with SMI, if T2DM was 
diagnosed first. 'Cases' who received a 
diagnosis of SMI before T2DM were not 
affected by this. Within estimators were 
applied in the regressions to examine the 
variations in outcomes among matched 
individuals only. Conditional logistic 
regression models, Poisson, or negative 
binomial models and stratified Cox 
proportional hazard models were applied, 
depending on the type of outcome variables. 
SMI status was treated as time 
dependent in survival analyses, and the 
proportional hazard assumption was 
tested by the inclusion of interaction 
effects between explanatory variables and 
time — interaction terms with statistically 
significant coefficients were retained in the 
final models. Goodness of fit was assessed 
by the C-statistic, the Akaike information 
criterion, and the Bayesian information 
criterion, as appropriate. Due to the extent 
of baseline characteristic data that were 
missing, each participant’s family history 
of diabetes, smoking status, and baseline 
biometrics were retained in the model 
only if they improved model fit. Further 
adjustments were made to account for 
Table 1. Baseline characteristics of patients with T2DM and SMI 
(cases) and patients with T2DM and no SMI (controls)
 Overall Cases Controls
Participantsa 9965 (100) 2192 (22.0) 7773 (78.0)
Controls per case   
 4   1599 (72.9)
 3   323 (14.7) 
 2   138 (6.3) 
 1   132 (6.0) 
Age at diagnosis in years, mean (SD)
 SMI  47.98 (17.40) 
 T2DM 57.83 (12.97) 56.81 (13.19) 58.12 (12.89)
SMI type   
 Schizophrenia   1161 (53.0) 
 Schizoaffective disorder  113 (5.2) 
 Bipolar disorder  701 (32.0) 
 Depression and psychosis  184 (8.4) 
 Other affective disorder  26 (1.2) 
 Mixed  7 (0.3) 
Age at start of follow-up 58.63 (12.83) 57.67 (13.11) 58.90 (12.74) 
in years, mean (SD)
Duration of T2DM in years, mean (SD) 0.82 (2.85) 0.89 (3.02) 0.80 (2.80)
Length of follow-up in years, mean (SD) 6.19 (4.43) 6.02 (4.45) 6.23 (4.43)
Family history of diabetes 1766 (17.7) 324 (14.8) 1442 (18.6)
Sex
 Male 4758 (47.7) 1051 (47.9) 3707 (47.7) 
 Female 5207 (52.3) 1141 (52.1) 4066 (52.3)
Ethnicity
 White 8095 (81.2) 1826 (83.3) 6269 (80.7)
 Asian 638 (6.4) 139 (6.3) 499 (6.4)
 Black 363 (3.6) 106 (4.8) 257 (3.3)
 Mixed, other and unknown 869 (8.7) 121 (5.5) 748 (9.6)
Deprivation quintile using IMD 2010   
 1 (least deprivation) 1490 (15.0) 279 (12.7) 1211 (15.6)
 2 1860 (18.7) 358 (16.3) 1502 (19.3)
 3 1984 (19.9) 415 (18.9) 1569 (20.2)
 4 2287 (23.0) 542 (24.7) 1745 (22.4)
 5 2334 (23.4) 595 (27.1) 1739 (22.4)
 Data missing 10 (0.1) 3 (0.1) 7 (0.1)
Comorbidities   
 CVD 1591 (16.0) 285 (13.0) 1306 (16.8)
 Hypertension 4318 (43.3) 734 (33.5) 3584 (46.1)
 Dementia 64 (0.6) 32 (1.5) 32 (0.4)
 Learning disability 40 (0.4) 19 (0.9) 21 (0.3)
 CCI comorbidity, mean (SD)  0.53 (0.78) 0.49 (0.73) 0.54 (0.79)
Medication type   
 Antidepressants 2585 (25.9) 1062 (48.4) 1523 (19.6)
 Antipsychotics   
  First generation 524 (5.3) 434 (19.8) 90 (1.2)
  Second generation 1009 (10.1) 957 (43.7) 52 (0.7)
 Antidiabetes 2164 (21.7) 521 (23.8) 1643 (21.1)
 Antihypertensives 5349 (53.7) 1000 (45.6) 4349 (56.0)
 Lipid-lowering 3361 (33.7) 684 (31.2) 2677 (34.4)
Smoking status   
 Non-smoker 2775 (27.8) 544 (24.8) 2231 (28.7)
 Ex-smoker 2049 (20.6) 390 (17.8) 1659 (21.3)
 Current smoker 1873 (18.8) 650 (29.7) 1223 (15.7)
 Missing data 3268 (32.8) 608 (27.7) 2660 (34.2)
 … continued
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duration of T2DM, death during follow-up, 
length of follow-up, and financial years. 
Stata (version 15) was used for all analyses.
RESULTS
Participant characteristics
Baseline characteristics of participants with 
and without SMI are summarised in Table 1. 
A total of 2192 people with T2DM and SMI 
were matched to 7773 people with T2DM 
and no SMI; 87.7% of participants with 
T2DM and SMI matched to three or four 
controls, 53.0% of cases had schizophrenia, 
and 32.0% had bipolar disorder. Proportions 
of participants with SMI were similar to 
those without SMI in terms of age at time 
of T2DM diagnosis and at start of follow-
up, sex, duration of T2DM, and follow-up 
length, but were more likely to live in areas 
of greatest deprivation, have dementia 
or learning disability, and less likely to 
have physical comorbidities recorded. 
People with SMI were also much more 
likely to be prescribed antidepressants and 
antipsychotics, and slightly less likely to 
be prescribed antihypertensive and lipid-
lowering medications.
Proportions of missing values were 
generally similar between people with and 
without SMI for smoking status, biometric 
variables, and level of deprivation, but BMI 
and smoking status were slightly better 
recorded for people with SMI. On average, 
people with SMI had slightly higher BMI 
and levels of serum cholesterol, lower 
mean HbA1c, and lower mean systolic and 
diastolic BP. 
Crude outcomes for the two participant 
groups are summarised in Table 2. People 
with SMI had, on average, a higher number 
of primary care consultations and received 
more health checks for BMI compared 
with those without SMI. The mean crude 
consultation rate was 13.65 per year for 
people with SMI, including 8.98 contacts 
with primary care physicians and 4.67 with 
practice nurses; for people without SMI, 
those rates were 11.18, 6.85, and 4.32 per 
year, respectively. Frequency of health 
checks for HbA1c and cholesterol levels 
were similar in both groups, whereas BP 
checks were fewer for people with SMI.
For CVD, people with SMI had lower 
crude risks for MI, PVD, angina, chronic 
IHD, and macrovascular complications 
combined; however, the crude prevalence 
of stroke was higher in people with SMI than 
in people without SMI. Hospital-admission 
rates for these conditions were similar 
between both groups, although emergency 
admission rates were slightly higher in 
those with SMI. All-cause and CVD-specific 
crude mortality rates were higher in people 
with SMI than in those without SMI. 
Average serum cholesterol levels and 
HbA1c levels (Figure 1) declined between 
2000/01 and 2006/07 for both groups, and 
then remained relatively stable thereafter. 
Average BP levels declined throughout the 
study period, and people with SMI had lower 
levels at all time points (Figure 2). 
Regression analyses 
The adjusted impact of SMI on outcomes 
is summarised in Table 3. Compared with 
participants without SMI, those with SMI 
had higher primary care consultation rates 
and were more likely to receive checks 
for their BP, cholesterol levels, and BMI. 
The estimated increase was 10% (incidence 
rate ratio [IRR] 1.101, 95% confidence 
interval [CI] = 1.069 to 1.134) for overall 
consultations, and 15% (IRR 1.149, 
95% CI = 1.111 to 1.118) for contacts 
with primary care physicians. Checks 
were increased by 2% (IRR 1.024, 95% 
CI = 1.003 to 1.046) for BP, 4% (IRR 1.038, 
95% CI = 1.019 to 1.058) for cholesterol, and 
7% (IRR 1.068, 95% CI = 1.044 to 1.093) for 
Table 1 Continued. Baseline characteristics of patients with T2DM 
and SMI (cases) and patients with T2DM and no SMI (controls)
 Overall Cases Controls
Biometric measures   
BMI, kg/m2, mean (SD) 32.66 (6.95) 32.97 (6.99) 32.56 (6.94)
 <20 62 (0.6) 12 (0.5) 50 (0.6)
 20–24 617 (6.2) 145 (6.6) 472 (6.1)
 25–29  1752 (17.6) 401 (18.3) 1351 (17.4)
 30–39 3004 (30.1)  733 (33.4) 2271 (29.2)
 ≥40 871 (8.7) 221 (10.1) 650 (8.4)
 Missing data 3659 (36.7) 680 (31.0) 2979 (38.3)
HbA1c, %, mean (SD) 7.88 (1.95)  7.82 (1.99) 7.90 (1.95)
 ≤7.5b 2998 (30.1) 672 (30.7) 2326 (29.9)
 >7.5b 2188 (22.0) 460 (21.0) 1728 (22.2)
 Missing data 4779 (48.0) 1060 (48.4) 3719 (47.8)
Total cholesterol, mmol/L, mean (SD)  5.30 (1.31) 5.36 (1.42) 5.28 (1.28)
 ≤5 3477 (34.9) 722 (32.9) 2755 (35.4)
 >5  4105 (41.2) 892 (40.7) 3212 (41.3)
 Missing data 2383 (23.9) 578 (26.4) 1805 (23.2)
Systolic BP, mmHg, mean (SD) 139.17 (18.28) 135.82 (18.16) 140.13 (18.21)
  ≤140 5154 (51.7) 1280 (58.4) 3874 (49.8) 
  >140 3306 (33.2) 605 (27.6) 2701 (34.7)
  Missing data 1505 (15.1) 307 (14.0) 1198 (15.4)
 Diastolic BP, mmHg, mean (SD)  81.87 (10.72) 81.47 (10.72) 81.99 (10.71)
  ≤80 4391 (44.1) 1011 (46.1) 3380 (43.5)
  >80 4069 (40.8) 874 (39.9) 3195 (41.1)
  Missing data 1505 (15.1) 307 (14.0) 1198 (15.4)
aData presented as n (%) unless otherwise stated. b58 mmol/mol. BMI = body mass index. BP = blood pressure. 
CCI = Charlson Comorbidity Index. CVD = cardiovascular disease. IMD = Index of Multiple Deprivation. SD = standard 
deviation. SMI = severe mental illness. T2DM = type 2 diabetes mellitus.
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BMI for people with SMI, compared with 
those without SMI. 
People with SMI were less likely to have 
a primary care diagnosis of angina (odds 
ratio [OR] 0.671, 95% CI = 0.450 to 1.001) 
but more likely to have a diagnosis of 
stroke (OR 1.381, 95% CI = 1.036 to 1.841). 
For emergency admissions, people with 
SMI had varied risks for different types of 
CVD, including increased risk for angina 
(IRR 1.532, 95% CI = 1.069 to 2.195) and 
stroke (IRR 1.440, 95% CI = 1.055 to 1.965), 
and decreased risk for MI (IRR 0.683, 
95% CI = 0.482 to 0.967). They were less 
likely to have an elective admission for 
CVD (IRR 0.644, 95% CI = 0.470 to 0.882) 
and had lower admission rates for chronic 
Table 2. Crude healthcare use and health outcomes of patients with T2DM and SMI (cases) and patients 
with T2DM and no SMI (controls)
 Overall Cases Controls
Participantsa 9965 (100) 2192 (22.0) 7773 (78.0)
Primary care consultations per year
 Overall
  Mean (SD) 11.72 (10.05) 13.65 (10.07) 11.18 (9.97)
  Median (range) 9.60 (0.00–365.30b) 11.10 (0.00–113.00) 9.20 (0.00–365.30b)
 Primary care physicians
  Mean (SD) 7.32 (7.77) 8.98 (7.83) 6.85 (7.69)
  Median (range) 5.70 (0.00–365.30b) 7.10 (0.00–91.30) 5.30 (0.00–365.30b)
 Practice nurses 
  Mean (SD) 4.40 (5.29) 4.67 (5.26) 4.32 (5.30)
  Median (range) 3.30 (0.00–143.40) 3.40 (0.00–68.30) 3.20 (0.00–143.40)
Health checks per year
 HbA1c
  Mean (SD) 1.80 (1.16) 1.78 (1.27) 1.81 (1.13)
  Median (range) 1.70 (0.00–45.70) 1.70 (0.00–28.10) 1.70 (0.00–45.70)
 BP
  Mean (SD) 3.01 (4.27) 2.93 (2.49) 3.03 (4.66)
  Median (range) 2.60 (0.00–365.30b) 2.50 (0.00–52.20) 2.60 (0.00–365.30b)
 Total cholesterol 
  Mean (SD) 1.35 (0.86) 1.38 (0.97) 1.35 (0.82)
  Median (range) 1.30 (0.00–26.10) 1.30 (0.00–26.10) 1.30 (0.00–13.50)
 BMI
  Mean (SD) 1.98 (4.07) 2.08 (1.95) 1.95 (4.49)
  Median (range) 1.60 (0.00–365.30b) 1.70 (0.00–30.40) 1.60 (0.00–365.30b)
Macrovascular complications — MI,  868 (8.7) 184 (8.4) 684 (8.8) 
PVD, and stroke — combined
MI 344 (3.5) 70 (3.2) 274 (3.5)
PVD 305 (3.1) 58 (2.6) 247 (3.2)
Stroke 293 (2.9) 72 (3.3) 221 (2.8)
Angina 324 (3.3) 55 (2.5) 269 (3.5)
Chronic IHD 101 (1.0) 17 (0.8) 84 (1.1)
Hospital admissions for CVD per year, mean (SD)
 Emergency 0.03 (1.20) 0.03 (0.25) 0.02 (0.18)
 Elective 0.01 (0.15) 0.01 (0.05) 0.01 (0.16)
 Angina (ICD-10 code: I20c) 0.01 (0.06) 0.01 (0.06) 0.01 (0.07)
 MI (ICD-10 codes: I21 and I22c) 0.01 (0.17) 0.01 (0.24) 0.01 (0.15)
 Chronic IHD (ICD-10 code: I25c) 0.01 (0.15) 0.01 (0.05) 0.01 (0.17)
 Stroke (ICD-10 codes: I60–I64c) 0.01 (0.07) 0.01 (0.08) 0.01 (0.07)
Mortality
 All-cause 1384 (13.9) 364 (16.6) 1020 (13.1)
 CVD 511 (5.1) 132 (6.0) 379 (4.9)
aData presented as n (%) unless otherwise stated. bHigh consultation and health-check rates reflect few consultations recorded over a short follow-up period. cICD-10 code(s) used 
to classify admission. BMI = body mass index. BP = blood pressure. CVD = cardiovascular disease. ICD-10 = International Classification of Diseases (10th revision). IHD = ischaemic 
heart disease. MI = myocardial infarction. PVD = peripheral vascular disease. SD = standard deviation. SMI = severe mental illness. T2DM = type 2 diabetes mellitus.
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IHD (IRR 0.682, 95% CI = 0.508 to 0.915) 
compared with people without SMI. 
For people with SMI, their all-cause 
mortality rate was 92% higher (hazard ratio 
[HR] 1.919, 95% CI = 1.602 to 2.300) and 
their CVD-specific mortality rate was 124% 
higher (HR 2.242, 95% CI = 1.547 to 3.250) 
than that of people without SMI. 
Full results of adjusted models are 
detailed in Supplementary Tables S1–S6. 
Predictors for more frequent consultations 
were greater deprivation, longer duration 
of T2DM, comorbidity, and some 
medications (antihypertensive, antidiabetes, 
antidepressants, and antipsychotics). 
Dementia was associated with fewer 
consultations. Higher frequencies of 
health checks were associated with lower 
levels of deprivation (for cholesterol and 
HbA1c checks), CCI comorbidities, use 
of medications, obesity, family history of 
diabetes, and higher biometric measures 
at baseline. 
History of CVD and use of lipid-lowering 
medications were the strongest predictors 
for future CVD events, such as hospital 
admissions. Baseline antihypertensive 
prescriptions were associated with 
increased risk of hospital admission for 
angina and stroke. Longer duration of T2DM 
was associated with increased risk of CVD 
admissions; greater deprivation, history of 
CVD, and the presence of comorbidities 




After adjusting for confounders, no 
evidence was found that people with 
SMI and diabetes experienced reduced 
access to routine primary care, such as 
consultations and physical health checks, 
than people with diabetes alone. People 
with SMI, compared with those without 
SMI, were, however, more likely to be 
socioeconomically disadvantaged, more 
likely to have some recorded conditions 
(for example, dementia), and were less 
likely to have others (for example, physical 
comorbidity). 
There were complex associations 
between SMI and the risk of CVD outcomes 
across diagnosis groups and healthcare 
settings: recorded prevalence of angina 
was lower for people with SMI, as were 
elective hospital-admission rates for 
CVD and emergency admission rates 
for MI. In contrast, emergency hospital-
admission rates for angina and stroke were 
substantially higher. Finally, people with 
SMI were more likely to die compared with 
those without SMI, and had more than 
double the risk of CVD-related mortality.
Strengths and limitations 
A large, linked, longitudinal dataset of 
individual primary care records was 
analysed, allowing for multiple elements 
along the care pathway for diabetes 
and CVD to be studied. In addition, the 
matched, nested, case–control study, 
along with the design and application of 
within estimators reduced the impact of 
unobserved confounders. The interrogation 
of multiple diagnosis groups can be 
considered as sensitivity checks of the 
key findings, and adjusting for medication 
prescriptions improved the identification of 
comorbidities — particularly for the physical 
long-term conditions in people with SMI. 
Furthermore, as patient characteristics in 
the CPRD database have been shown to 
be broadly representative of the general 
UK population in terms of age, sex, and 
ethnicity,22 the findings are likely to have 
wide generalisability. 
As with all studies that use routine 
healthcare records, limitations arise as a 
result of data accuracy and completeness of 
Figure 1. a) Average levels of serum total cholesterol 
(health outcomes), 2000–2016. b) Average HbA1c 
levels (health outcomes), 2000–2016. HbA1c = glycated 
haemoglobin. SMI = severe mental illness. 
T2DM = type 2 diabetes mellitus.
Figure 2. a) Average systolic blood pressure levels 
(health outcomes), 2000–2016. b) Average diastolic 
blood pressure levels (health outcomes), 2000–2016. 
BP = blood pressure. SMI = severe mental illness. 
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data. There were high levels of missing data 
for some variables and it was not possible 
to adjust for factors such as lifestyle, or 
for environmental and social determinants 
of health. In addition, coding behaviour is 
likely to vary by individual primary care staff 
and practices, presenting further potential 
errors in primary care records. Under the 
QOF, however, primary care providers have 
been incentivised to maintain registers 
of various conditions, including SMI; as 
such, the authors expect that diagnosis is 
less likely to be affected by this limitation 
compared with other areas. 
Data on pathways, including referral 
and outpatient records, were limited; this 
restricted exploration of service use along 
the full care pathway and potential service 
gaps. Severity of mental illness or diabetes 
is not routinely recorded and could not be 
inferred reliably. 
Heart failure, which is more common 
in people with diabetes compared to the 
general population, was not analysed; 
the authors did not make inference with 
regard to the prevalence and outcome of 
heart failure, and did not expect this would 
significantly affect findings. 
Diagnosis order between SMI and T2DM 
is an important factor in relation to the 
disease  development mechanism, patient 
demographic distribution, and potential 
impact on health outcomes. In this study, 
however, the authors did not separate 
those diagnosed with SMI first from those 
who were diagnosed with T2DM first and 
therefore had produced 'aggregated' 
results. More detailed analysis by diagnosis 
order would be helpful for future research.
As with all observational studies, it was 
not possible to control for unobserved 
confounders and systematic measurement 
biases that might lead to an over- or 
underestimatation of associations between 
risk factors and outcomes.
Comparison with existing literature
The analysis of both primary care 
and hospital-admission records has 
highlighted two potential inequalities in the 
identification and subsequent treatment of 
CVD. First, compared with people without 
SMI, diagnosis of angina in primary 
care was lower in people with SMI but 
emergency admission rates were higher. 
This may reflect more rapid and severe 
onset, presentation, and diagnostic delay, 
and/or greater preference for emergency 
hospital services as the first point of contact 
for people with SMI who are experiencing 
chest pain. The lower admission rate 
for MI might also be related to this and 
suggests fewer, but more fatal, admissions 
for coronary heart disease, rather than 
an indicator of better outcomes. Second, 
the lower diagnosis and elective admission 
rates for IHD in people with SMI suggests 
that this population was less likely to be 
referred to cardiovascular specialist care; 
this finding is consistent with those of an 
Australian study.26
There are several interrelated potential 
explanations. Reasons for systematic 
underdiagnosis of CVD could include 
symptom under-reporting by people 
with SMI, diagnostic overshadowing, and 
a lack of confidence by mental health 
professionals to diagnose and manage 
physical comorbidities.27 Primary care 
providers might be reluctant to prescribe 
medications for long-term conditions 
Table 3. Adjusted impact of SMI on healthcare use and health 
outcomesa
 Diagnosis of SMI
  Adjusted IRR 95% CI P-value
Primary care consultations
 Overall 1.101 1.069 to 1.134 <0.001
 Primary care physicians 1.149 1.111 to 1.188 <0.001
 Practice nurses 1.020 0.982 to 1.060 0.297
Physical health checks   
 BP 1.024 1.003 to 1.046 0.028
 Cholesterol 1.038 1.019 to 1.058 <0.001
 HbA1c 0.989 0.970 to 1.009 0.297
 BMI 1.068 1.044 to 1.093 <0.001
Hospital admissions for CVD   
 Emergency 1.149 0.959 to 1.378 0.132
  Angina (ICD-10 code: I20b) 1.532 1.069 to 2.195 0.020
  MI (ICD-10 codes: I21 and I22b) 0.683 0.482 to 0.967 0.032
  Stroke (ICD-10 codes: I60–I64b) 1.440 1.055 to 1.965 0.022
 Elective 0.644 0.470 to 0.882 0.006
  Chronic IHD (ICD-10 code: I25b) 0.682 0.508 to 0.915 0.011
  Adjusted ORb 95% CI P-value
Primary care diagnosis of CVD   
 Macrovascular complications 0.970 0.794 to 1.185 0.765 
 combined (MI, stroke, and PVD)
 Angina 0.671 0.450 to 1.001 0.050
 MI 0.929 0.698 to 1.236 0.613
 Stroke 1.381 1.036 to 1.841 0.028
 Chronic IHD 0.742 0.394 to 1.399 0.356
  Adjusted HR 95% CI P-value
Mortality   
 All-cause 1.919 1.602 to 2.300 <0.001
 CVD 2.242 1.547 to 3.250 <0.001
aModels were adjusted for: age; ethnicity; level of deprivation; financial years; statistically significant confounders 
in comorbidities; medications use; duration and family history of T2DM; death in follow-up period; smoking 
status; and biometric measures. bICD-10 code(s) used to classify admissions BMI = body mass index. BP = blood 
pressure. CVD = cardiovascular disease. HR = hazard ratio. ICD-10 = International Classification of Diseases (10th 
revision). IHD = ischaemic heart disease. IRR = incidence rate ratio. MI = myocardial infarction. OR = odds ratio. 
PVD = peripheral vascular disease. SMI = severe mental illness. T2DM = type 2 diabetes mellitus.
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and refer people with SMI for standard 
surgical procedures,28,29 perhaps due to 
perceived psychological stress, capacity 
for post-operative care, and a higher risk 
of developing complications after surgical 
interventions. A lack of integration among 
primary care, specialist physical healthcare, 
and psychiatric services may have made 
navigation of the care pathway more difficult 
for people with SMI.30,31
Implications for practice
This analysis shows that the greatest 
challenge to the healthcare system, 
policymakers, and researchers who are 
interested in addressing the issue of health 
inequality in people with SM, is no longer 
general monitoring of metabolic risk factors 
as incentivised by national guidelines, as 
these now appear to be equally delivered to 
people with and without SMI. Rather, people 
with SMI appear to be underdiagnosed for 
CVD in primary care and, consequently, 
have poorer access to specialist and elective 
hospital care, leading to an elevated risk of 
cardiovascular mortality in this population. 
Policies to reduce excess deaths should, 
therefore, focus on activities that occur 
earlier in the care pathway to facilitate early 
diagnosis and timely treatment for CVD. 
Current QOF targets do not consider 
the implications of antipsychotic medication 
and other challenges that people with SMI 
face in managing their diabetes.32 Living 
with greater levels of deprivation can 
also increase the likelihood of developing 
chronic health problems for people with 
SMI, and reduce capacity to successfully 
manage them. Policies should be designed 
to encourage primary care providers to 
initiate effective conversations with patients 
with SMI and their carers on both mental 
and physical health needs, improve 
coordination between primary care and 
specialist physical healthcare services, and 
develop strategies for tackling the particular 
challenges faced by people with SMI who 
are dealing with multimorbidity.
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